Fäldt R, Ankerst J
Cancer Immunol Immunother. 1983;15(2):69-77. doi: 10.1007/BF00199693.
A 125I-protein A-binding assay detecting antibodies to cell surface antigens on human blood cells was developed and evaluated using sera from multitransfused nonleukemic patients sensitized against HLA antigens. The binding assay was found to be reproducible and more sensitive than conventional HLA testing. Seven patients with acute myelogenous leukemia and two patients with acute lymphoblastic leukemia successfully treated by chemotherapy were then investigated. Sera from seven of the patients studied in partial or complete remission demonstrated significant binding to autochthonous leukemic cells obtained from bone marrow or peripheral blood. In two cases sera taken during the leukemic stage demonstrated the most pronounced binding to the patients' own leukemic cells. Sera from four patients with demonstrable significant binding to autochthonous leukemic cells failed to bind to autochthonous remission cells when both types of target cells were tested in parallel. Differences in serum concentrations of IgG, IgA, and IgM were not the cause of the demonstrated increased binding of leukemic sera to autochthonous target cells. We propose that the 125I-protein A-binding assay presented in this paper detects antibodies reacting selectively with acute leukemia cells.
开发了一种检测人血细胞表面抗原抗体的125I-蛋白A结合试验，并使用对HLA抗原致敏的多次输血非白血病患者的血清进行评估。发现该结合试验具有可重复性，且比传统的HLA检测更灵敏。随后对7例经化疗成功治疗的急性髓性白血病患者和2例急性淋巴细胞白血病患者进行了研究。在部分或完全缓解的7例研究患者的血清中，显示出与从骨髓或外周血获得的自身白血病细胞有显著结合。在2例病例中，白血病阶段采集的血清与患者自身的白血病细胞结合最为明显。当同时平行检测两种类型的靶细胞时，4例血清与自身白血病细胞有明显显著结合的患者的血清未能与自身缓解期细胞结合。IgG、IgA和IgM血清浓度的差异不是白血病血清与自身靶细胞结合增加的原因。我们认为本文介绍的125I-蛋白A结合试验检测到了与急性白血病细胞选择性反应的抗体。
